Prin Sungwan

Honjo, 8600811, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma.

Journal: Cancer immunology, immunotherapy : CII

Published: December 31, 2025

Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer.

Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer.

Journal: Investigational new drugs

Published: May 26, 2025

Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.

Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma.

Journal: Oncology research

Published: March 10, 2025

Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.

Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms.

Journal: International immunopharmacology

Published: April 30, 2024

Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma In Vitro and In Vivo.

Anti-Tumor and Chemosensitizing Effects of the CDK Inhibitor Dinaciclib on Cholangiocarcinoma In Vitro and In Vivo.

Journal: In vivo (Athens, Greece)

Published: April 17, 2024

Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.

Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line.

Journal: Human cell

Published: February 10, 2024

Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma.

Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma.

Journal: Anticancer research

Published: December 25, 2023

Bioinformatics analysis identified CDC20 as a potential drug target for cholangiocarcinoma.

Bioinformatics analysis identified CDC20 as a potential drug target for cholangiocarcinoma.

Journal: PeerJ

Published: September 03, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026